Scarica l'app Stockscreener
4.30
1.83%
-0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FBIO Giù?
Forum
Previsione
Frazionamento azionario
Fortress Biotech Inc Borsa (FBIO) Ultime notizie
Fortress Biotech (NASDAQ:FBIOP) Shares Up 2.4% – Should You Buy? - Defense World
Will Fortress Biotech Inc.(CNB0) stock rise with strong economyMarket Sentiment Summary & Risk Managed Investment Signals - ulpravda.ru
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Aug Rallies: Can Fortress Biotech Inc. stock hit record highs againBond Market & AI Optimized Trade Strategies - ulpravda.ru
Will Fortress Biotech Inc. stock benefit from AI adoptionOptions Play & Short-Term Trading Alerts - ulpravda.ru
Can Fortress Biotech Inc. stock hit record highs againMarket Movement Recap & Daily Profit Maximizing Tips - ulpravda.ru
How Fortress Biotech Inc. stock compares to industry benchmarksJobs Report & Real-Time Buy Signal Alerts - ulpravda.ru
Will Fortress Biotech Inc. stock outperform international peersJuly 2025 Review & Expert Verified Stock Movement Alerts - ulpravda.ru
Is Fortress Biotech Inc.(CNB0) stock testing key supportWeekly Investment Report & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Fortress Biotech amends credit agreement with Oaktree - MSN
Fortress Biotech (NASDAQ: FBIO) reports 13.4% Avenue (ATXI) stake with voting control - Stock Titan
FBIO Stock Price, Forecast & Analysis | FORTRESS BIOTECH INC (NASDAQ:FBIO) - Chartmill
Head-To-Head Comparison: Fortress Biotech (NASDAQ:FBIO) & WAVE Life Sciences (NASDAQ:WVE) - Defense World
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults - ADVFN
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
How Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Affects Rotational Strategy Timing - Stock Traders Daily
Signal Recap: Will Fortress Biotech Inc stock benefit from AI adoptionMarket Sentiment Report & Consistent Profit Trading Strategies - moha.gov.vn
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
What analysts say about Fortress Biotech Inc stockEx-Dividend Date Alerts & High Yield Portfolio Growth - earlytimes.in
(FBIOP) Risk Channels and Responsive Allocation - Stock Traders Daily
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 28% Price Jump - 富途牛牛
Is Fortress Biotech Inc.(CNB0) stock resilient in recession scenarios2025 Market WrapUp & AI Powered Market Trend Analysis - Улправда
Fortress Biotech (NASDAQ: FBIO) registers 600,000 shares for Oaktree resale - Stock Titan
What momentum indicators show for Fortress Biotech Inc. stockJuly 2025 Big Picture & Weekly Setup with High ROI Potential - Улправда
Triplex vaccine enters Phase 2 trial in stem cell donors - MSN
Fortress Biotech’s CUTX-101 NDA resubmission accepted by FDA - MSN
Fortress Biotech (FBIO) files for 600K share offering by selling stockholders - StreetInsider
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump - simplywall.st
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Fortress Biotech (Nasdaq: FBIO) resale filing covers 600,000 shares for Oaktree - Stock Titan
Fortress Biotech Amends Credit Agreement with Oaktree - TipRanks
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Fortress Biotech (NASDAQ: FBIO) extends loan maturity and grants warrants - Stock Titan
Fortress Biotech, Inc. Enters into First Amendment to Credit Agreement - marketscreener.com
Fortress Biotech, Inc. and Cyprium Therapeutics, Inc. Announce FDA Acceptance of CUTX-101 NDA Resubmission - marketscreener.com
FDA sets new PDUFA date for Fortress Biotech’s Menkes disease therapy - Investing.com Nigeria
Fortress Biotech Rises After FDA Accepts Application for Menkes Treatment - marketscreener.com
Fortress Biotech, Cyprium announce FDA acceptance of CUTX-101 NDA resubmission - TipRanks
Fortress Biotech, Cyprium get FDA acceptance for CUTX-101 NDA resubmission - marketscreener.com
Fortress Biotech, Cyprium Get FDA Acceptance for CUTX-101 NDA Resubmission - TradingView — Track All Markets
Fortress Biotech’s CUTX-101 NDA Resubmission Accepted by FDA - TipRanks
Fortress Biotech (FBIO) Resubmits Application for Menkes Disease Treatment - GuruFocus
Fortress Biotech Announces FDA Acceptance of CUTX-101 NDA Resubmission - TradingView — Track All Markets
[8-K] Fortress Biotech, Inc. Reports Material Event | FBIO SEC FilingForm 8-K - Stock Titan
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission - GlobeNewswire
Fortress Biotech, Inc. (NASDAQ:FBIO) Q3 2025 Earnings Call Transcript - MSN
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - GlobeNewswire
(FBIOP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Published on: 2025-12-08 06:59:10 - moha.gov.vn
FBIOP | Fortress Biotech, Inc. 9.375% Stock Data, Price & News - Quiver Quantitative
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Avenue Therapeutics (NASDAQ: ATXI) 2025 proxy on director elections, KPMG audit and Fortress control - Stock Titan
Is Fortress Biotech Inc.(CNB0) stock undervalued historicallyWeekly Trading Summary & Pattern Based Trade Signal System - Newser
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):